Prostate cancer is the most common cancer in men and is second most common cause of cancer deaths. Importantly, the annual rates of prostate cancer incidence continue to rise. This session will delve ...

A new study designs drugs that bind to intrinsically disordered proteins that are extremely difficult to target due to their flexible nature.

Verana Health ®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world ...

Artera has secured CE marking under the European Union In Vitro Diagnostic Regulation (EU IVDR) for its ArteraAI prostate ...

Prostate cancer stands as a prevalent threat to men's health, ranking second in cancer-related deaths in the United States. Each year, approximately 250,000 men in the U.S. receive a prostate cancer ...

Individual patient data (IPD) analysis of early PSA nadir in ARASENS, LATITUDE, and TITAN: Training and validation of a novel model. Assessing genomic instability (GI) by shallow whole-genome ...

Benefits include better discrimination between risk levels. (HealthDay News) — Patient-centered pathology reports (PCPR) help patients to understand prostate cancer results better than current ...

Rapid and deep prostate-specific antigen (PSA) response to apalutamide plus ADT and survival in metastatic castration-sensitive prostate cancer (mCSPC) in real world practice in the US (OASIS Project) ...

Advanced age raises mortality risk in metastatic prostate cancer. Learn how PSA, tumour grade, and treatment influence ...

HNL Lab Medicine is the laboratory partner affiliated with Lehigh Valley Health Network, part of Jefferson Health, which includes 14 hospital campuses and 981 licensed acute beds across its flagship ...